Zhi Tong Cai Jing·2026-01-08 03:08Core Viewpoint - The price of experimental monkeys, particularly for the 3-5 year old crab-eating macaques, has surged to 140,000 yuan each, indicating a supply-demand imbalance in the market. This trend is expected to benefit companies like Zhaoyan New Drug, which possess valuable resources in this area [1] Company Summary - Zhaoyan New Drug's stock has seen an increase of over 4%, currently trading at 24 Hong Kong dollars with a transaction volume of 108 million Hong Kong dollars [1] - The company has access to high-quality and scarce experimental monkey resources, which contribute to a stable profit base through annual sales of a certain number of monkeys for internal use [1] - In the context of tightening supply of experimental monkeys, Zhaoyan New Drug may gain stronger bargaining power, potentially leading to increased order rates and the ability to charge premium service fees [1] Industry Summary - The supply of experimental monkeys is declining while demand is stabilizing and recovering, driven by new technologies such as small nucleic acids and CAR-T, which require the use of experimental monkeys [1] - The gap between supply and demand for experimental monkeys is widening, leading to an upward trend in monkey prices [1]